#AVCT 6 Dec 2022 - Prometheus released results of two P2 (12-week) studies. Off the back of this data they raised $500m (Dec 2022). 4 months later (Apr 2023) they were bought out for $10.8Bn ($193 per share). Negotiation from a position of strength. Basic stuff.

Volume day. #AVCT

This is exactly the type of orphan drug which receives expedited approval from the FDA. This revenue stream is close (~2027/8) on yearly sales which would represent well over half Avacta’s current market cap at these levels. #AVCT

“The Board's decision to raise funds enables Avacta to retain 100% ownership” #AVCT Bluff ? In a position of strength…

#AVCT

#AVCT The issue of chemotherapy safety is everywhere amongst clinicians. Especially into combo regimens. Rightly so. Consider what a platform to reduce these side effects means to the community and patients.

At #ESMO25 we had the pleasure of speaking with Tap directly who was very generous with his time. Our investment conviction has only grown. With #AVCT now fully funded; more than doubling the PFS in SGC; due to IND 6103; and present 6207 at AACR, we are primed to disrupt.

This is the crux of it. ADCs require high DARs (drug to antibody ratios) The DAR for Enhertu is 8, requiring 8 molecules of the payload (DXd, a top1 inhibitor) to be conjugated per antibody molecule. The cost and complexity for #AVCT’s 6103 is polar opposite.

Please note that an Investor Meet Company update will be going out via the platform tomorrow at around 2pm. The update will also be shared on the Avacta website and on social media in due course. Follow Avacta updates on the IMC platform here: investormeetcompany.com/companies/avac… #AVCT

#AVCT has STILL not hit median PFS in Phase 1a salivary gland cancer…

#AVCT

Novartis 👀 on #AVCT

#AVCT FortySeven Oct 2019 - $6 Mar 2020 - sold for $95 ($4.9Bn) 5 month move on P1b data reveal: $6>$95 Did FortySeven partner any drugs before Gilead's $4.9B takeover in March 2020? Yes. Small amounts across x2 deals and x2 non monetary collabs. 🤝 Ono Pharma (July 2019):